Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

NCT ID: NCT06315205

Last Updated: 2026-01-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-26
• Study Completion Date: 2026-02-28

Brief Summary

This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.

Detailed Description

The study consists of 1 Screening Period and 2 treatment periods. Evaluation of eligibility and allocation of subject number to the volunteers will be performed after Screening. It is planned that subjects will be enrolled in three groups of approximately 30 subjects in each group (Groups 1 to 3), in order to ensure 15 completed subjects per group in Treatment Period 1 and Treatment Period 2. In Treatment Period 1, each subject will sequentially receive 1 dose daily of oral Femara (2.5 mg) over a period of 14 days followed by a single intramuscular (IM) dose of Letrozole LEBE (after a washout period) in Treatment Period 2. Ascending doses of Letrozole LEBE will be given to Groups 1, 2 and 3. Safety and tolerability will be assessed in all groups by the incidence and severity of Adverse Events (AEs) and Serious AEs (SAEs), concomitant medication use, vital sign assessments, clinical laboratory evaluations, 12 lead ECGs, physical examination, and body weight/BMI. The end of the clinical trial will be the last visit of the last subject at Day 197 of Treatment Period 2 or any additionally required 4-weeks safety follow up visits, when plasma levels of letrozole are detectable, whichever occurs later. Those remaining subjects with detectable plasma levels of letrozole could be followed every 4 weeks.

The sample size was estimated based on a minimum number necessary to obtain a preliminary assessment regarding the drug's PK and safety profile over the planned dose range. No formal sample size calculation was made for this study.

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1: Letrozol LEBE 75 mg

Group Type: EXPERIMENTAL

Letrozole LEBE 75 mg

Intervention Type: DRUG

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg

Cohort 2: Letrozol LEBE 150 mg

Group Type: EXPERIMENTAL

Letrozole LEBE 150 mg

Intervention Type: DRUG

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg

Cohort 3: Letrozol LEBE 225 mg

Group Type: EXPERIMENTAL

Letrozole LEBE 225 mg

Intervention Type: DRUG

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg

Interventions

Letrozole LEBE 75 mg

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg

Intervention Type: DRUG

Letrozole LEBE 150 mg

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg

Intervention Type: DRUG

Letrozole LEBE 225 mg

14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy post-menopausal women.
• Capable of providing informed consent.
• Weight of ≥50 kg and a BMI ≥19 and ≤39 kg/m2.
• Subjects should be able to communicate with clinic staff.

Exclusion Criteria

• Subjects who have a history of allergy or hypersensitivity to letrozole or any of the inactive ingredients.
• Subjects who have a history of galactose intolerance, severe hereditary lactase deficiency glucose-galactose malabsorption.
• Subjects who have used estrogen or progesterone hormone replacement therapy, thyroid replacement therapy, oral contraceptives, androgens, luteinizing hormone (LH) releasing hormone analogs, prolactin inhibitors, or antiandrogens within prior to Screening.
• Subjects who have used: any medications including St. John's wort or any medications or products known to be potent or moderate inhibitors of CYP P450 3A4.
• Subjects who have been diagnosed with osteoporosis.
• Subjects who have an abnormality at Screening or prior to first dose that in the opinion of the investigator increases the risk of participating in the study.
• Subjects who have any clinically significant abnormal physical examination or laboratory safety findings at screening.
• Subjects who have relevant diseases or clinically significant abnormal relevant findings at Screening, as determined by medical history, physical examination, laboratory, ECG, DEXA, and breast and pelvic examination.
• Subjects who have history of any significant chronic disease.
• History of cancer within the past 5 years with the exception of non-melanoma skin cancer.
• Subjects who have a history of drug-dependence, and recent history of alcoholism or abuse of alcohol.
• Subjects who have received a drug in research or have participated in other clinical trials within 90 days, prior to dosing.
• Any other unspecified reason that, in the opinion of the investigator (or designee) or sponsor, makes the subject unsuitable for enrolment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Rovi Pharmaceuticals Laboratories

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Investigational Site number CZ-01

Prague, , Czechia

Countries

Czechia

Other Identifiers

2023-503948-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ROV-LEBE-2023-01

Identifier Type: -

Identifier Source: org_study_id